Purity 99% Lapatinib Raw Powder Lapatinib Ditosylate Powder Pharmaceutical Intermediate Lapatinib

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Model NO.: Dsung-Lapatinib
• Product Name: Lapatinib
• Appearance: Light Yellow or Almost White Crystalline Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical Intermediate
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 231277-92-2
• Mf: C29h26clfn4o4s
• MW: 581.057543
• Density: 1.381
• Melting Point: 136-140 C
• Boiling Point: 750.7 C at 760 Mmhg
• Refractive Index: 1.645
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 500 Kg/Month

Product Description

Purity 99% Lapatinib Raw Powder Lapatinib Ditosylate Powder Pharmaceutical Intermediate Lapatinib

 

Product Description

Product Details

Product Name	Lapatinib
Appearance	Light yellow or almost white crystalline powder
CAS No.	231277-92-2
MF	C29H26ClFN4O4S
MW	581.057543

Lapatinib is a chemical. Chemical name N-[3-chloro-4 -[(3-fluorophenyl) methoxy] phenyl]-6-[5-[(2-methylsulfonyl ethyl amino) methyl] -2-furanyl] quinazolin-4-amine, molecular formula C29H26ClFN4O4S, molecular weight 581.05800. Lapatinib is an antitumor drug mainly used in combination with capecitabine for the treatment of advanced or metastatic breast cancer treated with anthracycline, paclitaxel, trastuzumab (Herceptin).

Application & Function

1. Lapatinib (CAS 231277-92-2) is a small molecule kinase inhibitor that is used in the treatment of certain types of breast cancer.      It works by inhibiting the activity of two proteins that are involved in the growth and spread of cancer cells: epidermal grow th fact or receptor (EGFR) and human epidermal growth fac tor receptor 2 (HER2).
2. The main function of Lapatinib is to block the tyrosine kinase activity of EGFR and HER2 receptors, which are often overexpressed in breast cancer cells, leading to uncontrolled growth and proliferation of cancer cells. By inhibiting the activity of these receptors, Lapatinib can slow down or stop the growth of cancer cells, thus helping to treat breast cancer.
3. Lapatinib is indicated in combination with capecitabine for the treatment of advanced or metastatic breast cancer with prior treatment including anthracycline, paclitaxel, trastuzumab (Herceptin) and ErbB-2 overexpression.

Specification